Clinical bottom line
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative therapy in managing heart failure (HF) among patients with type 2 diabetes mellitus (T2DM). Evidence supports their efficacy in reducing hospitalization rates and cardiovascular mortality in both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). These agents also confer renal protection and improve metabolic parameters, positioning them as key components in the integrated management of cardio-renal-metabolic syndrome.
What the evidence shows
SGLT2 inhibitors improve clinical outcomes in HF patients with and without diabetes by mechanisms beyond glycemic control, including natriuresis, blood pressure reduction, and modulation of myocardial metabolism. Verbrugge et al. (2017) provided early clinical insights into the cardiovascular benefits of SGLT2 inhibitors in diabetic HF populations, highlighting reductions in HF hospitalizations and all-cause mortality.
More recent reviews by Grigoriou et al. (2025) emphasize the expanding role of SGLT2 inhibitors within the cardio-renal-metabolic syndrome framework, noting their capacity to attenuate disease progression through multifaceted effects on cardiac remodeling, renal function, and systemic inflammation.
In HFpEF, traditionally lacking effective therapies, Heath et al. (2022) discuss emerging evidence supporting SGLT2 inhibitors’ benefits in improving functional capacity and reducing HF events, marking a new therapeutic horizon.
Mekala Tejaswi et al. (2023) summarize clinical trial data demonstrating consistent efficacy of SGLT2 inhibitors across diverse HF phenotypes, with favorable safety profiles. They also address the management of hyperkalemia, a common comorbidity in HF, as reviewed by Beavers et al. (2025), underscoring the importance of comprehensive electrolyte monitoring during therapy.
Nandave Mukesh et al. (2024) highlight unmet needs and future directions, including optimizing patient selection and integrating SGLT2 inhibitors with other HF therapies to maximize cardiometabolic benefits.
Caveats and uncertainty
While robust, much of the evidence derives from large randomized controlled trials with selected populations, potentially limiting generalizability to all clinical settings.
Long-term safety data, especially in patients with advanced renal impairment or complex comorbidities, require further elucidation.
The precise mechanisms by which SGLT2 inhibitors confer cardiac benefits remain incompletely understood, complicating personalized therapy optimization.
Cost and access issues may limit widespread adoption in some healthcare systems.
How this may change practice
Clinicians should consider early initiation of SGLT2 inhibitors in patients with T2DM and HF, regardless of ejection fraction, to reduce morbidity and mortality.
Routine monitoring of renal function and electrolytes, including potassium, is essential to mitigate adverse effects.
Integration of SGLT2 inhibitors into multidisciplinary cardio-renal-metabolic care pathways can enhance patient outcomes.
Ongoing education and collaboration with cardiology and nephrology specialists will facilitate optimal use of these agents.
Future guidelines are likely to further endorse SGLT2 inhibitors as foundational therapy in HF management among diabetic patients.